Evidence map›Paper›PMID 39886466›Full record

ArticleiScience2025

Imaging of biphasic signalosomes constructed by checkpoint receptor 2B4 in conventional and chimeric antigen receptor-T cells.

Ryohei Matsushima, Ei Wakamatsu, Hiroaki Machiyama, Wataru Nishi, Yosuke Yoshida, Tetsushi Nishikawa, Hiroko Toyota, Masae Furuhata, Hitoshi Nishijima, Arata Takeuchi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ryohei MatsushimaDepartment of Thoracic Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Ei WakamatsuDepartment of Immunology, Tokyo Medical University, Tokyo 160-8402, Japan.
Hiroaki MachiyamaDepartment of Immunology, Tokyo Medical University, Tokyo 160-8402, Japan.
Wataru NishiDepartment of Thoracic Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Yosuke YoshidaDepartment of Immunology, Tokyo Medical University, Tokyo 160-8402, Japan.
Tetsushi NishikawaDepartment of Immunology, Tokyo Medical University, Tokyo 160-8402, Japan.
Hiroko ToyotaDepartment of Immunology, Tokyo Medical University, Tokyo 160-8402, Japan.
Masae FuruhataDepartment of Immunology, Tokyo Medical University, Tokyo 160-8402, Japan.
Hitoshi NishijimaDepartment of Immunology, Tokyo Medical University, Tokyo 160-8402, Japan.
Arata TakeuchiDepartment of Immunology, Tokyo Medical University, Tokyo 160-8402, Japan.
Makoto SuzukiDepartment of Thoracic Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Tadashi YokosukaDepartment of Immunology, Tokyo Medical University, Tokyo 160-8402, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A co-signaling receptor, 2B4, has dual effects in immune cells, but its actual functions in T cells remain elusive. Here, using super-resolution imaging technology with an immunological synapse model, we showed that 2B4 forms "2B4 microclusters" immediately after 2B4-CD48 binding. A lipid phosphatase, SHIP-1, subsequently combined with 2B4 to form coinhibitory signalosomes, leading to the suppression of cytokine production. An activating adapter, SLAM-associated protein (SAP), attenuated the clustering of SHIP-1 and recruited a kinase, Fyn, enhancing the Vav1 signaling pathway as costimulatory signalosomes. Furthermore, we found that a chimeric antigen receptor with a 2B4 tail (2B4-CAR) retained the original signal transduction mechanism of 2B4. With endogenous levels of SAP expression, 2B4-CAR-T cells exposed sufficient antitumor efficacy

Indexed as

Cell biologyImmunologyMethodology in biological sciences

Identifiers

PMID39886466
PMCPMC11780131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.